Handelsavisen
prelaunch
Companies ›Healthcare ›RPGL.NS
RP
RPGL.NS — NSE (India) Pharmaceuticals

RPG Life Sciences Ltd

$2 292,50
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
LatestRPG Life Sciences acquires Actis Generics to expand API footprint
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,84 %
Op margin
20,4 %
ROE
—
Net margin
16,2 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$9,70
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

RPG Life Sciences Ltd is a pharmaceutical company that develops and markets a range of healthcare products, primarily in the Indian market.

Business. RPG Life Sciences Ltd (RPGL.NS) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the development and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific segment or geographic breakdowns are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

1
  • MARKETSRPG Life Sciences acquires Actis Generics to expand API footprint2026-07-30

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RPGL.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · 2026-07-30

    Composite-score breakdown

    Synthesis

    Business

    RPG Life Sciences Ltd (RPGL.NS) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the development and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific segment or geographic breakdowns are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    RPG Life Sciences has a revenue of INR 1,654.20 million and a net income of INR 267.60 million, indicating a net margin of 16.18%. The company's operating income of INR 337.80 million suggests a strong operating margin of 20.42%, which is a key indicator of its operational efficiency.

    The company's profitability is further reflected in its gross profit of INR 1,104.10 million, translating to a gross margin of 66.75%. These metrics suggest that RPG Life Sciences is effectively managing its production and operational costs, which is a positive sign for its financial health.

    RPG Life Sciences operates primarily in the Indian market, and its revenue is concentrated in this region. The company does not disclose specific segment or geographic breakdowns in its latest financials, making it difficult to assess the diversification of its revenue streams.

    The company's growth trajectory is not clearly defined in the latest financial data, as there are no specific projections or historical growth rates provided. However, the current revenue and net income figures suggest a stable financial position.

    The risk assessment for RPG Life Sciences indicates a low dilution risk, with no significant dilution potential identified in the latest financial data. However, the liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.

    Recent events and filings for RPG Life Sciences do not indicate any major changes or risks that would significantly impact its financial position. The company's latest financial data does not include any recent events or transcripts that would provide additional insight into its operations or strategic direction.

    Key takeaways
    • RPG Life Sciences has a strong net margin of 16.18%, indicating effective cost management and profitability.
    • The company's gross margin of 66.75% suggests efficient production and operational processes.
    • RPG Life Sciences' revenue is primarily concentrated in the Indian market, with no disclosed segment or geographic diversification.
    • The company's liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.
    • RPG Life Sciences has a low dilution risk, with no significant dilution potential identified in the latest financial data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-04-30
    FY 2024 · Full-year highlights

    Revenue INR 5.82B, +13,5% YoY; Operating income +26,3% YoY.

    RevenueINR 5.82B+13,5 % YoY
    Operating incomeINR 1.11B+26,3 % YoY
    Net incomeINR 876.6M+29,6 % YoY
    Free cash flowINR 156.5M−54,7 % YoY
    EPS—
    Operating cash flowINR 943.6M+3,9 % YoY
    Financials
    Income statement
    RevenueINR 5.82B
    Gross profitINR 3.73B
    Operating incomeINR 1.11B
    Net incomeINR 876.6M
    Margins
    Gross margin64.2%
    Operating margin19.1%
    Net margin15.1%
    FCF margin2.7%
    Balance sheet
    Total assetsINR 5.13B
    Total liabilitiesINR 1.38B
    Total equityINR 3.75B
    Cash & equivalentsINR 170.0M
    Long-term debtINR 0.00
    Cash flow
    Operating cash flowINR 943.6M
    CapEx-INR 692.3M
    Free cash flowINR 156.5M
    SBC—
    P&L flow · revenue → net income
    Revenue INR 1.65BOperating costs INR 1.32BNet income INR 267.6M
    Highlights
    • ▍Revenue INR 5.82B, +13,5% YoY
    • ▍Operating income +26,3% YoY
    • ▍Net income +29,6% YoY
    • ▍Free cash flow −54,7% YoY
    • ▍Net margin 15.1%

    Valuation FY

    Market price
    $2 292,50
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Enterprise Application Software—
    low · business_description · 2026-07-03
    Software Consulting Services—
    low · business_description · 2026-07-03
    Software Support & Maintenance—
    low · business_description · 2026-07-03

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin20,4 %Above P75
    Net Margin16,2 %Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • RPG Life Sciences Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    Net buying1 buys · 17 sellsnet $7,8M2 insiders · last 365d
    • Ng Hao FengDirector, 10% owner · Class A Ordinary SharesOther 505 664 @ $1,94$981K · 2026-05-04
    • Ng Hao FengDirector, 10% owner · Class B Ordinary SharesOther 505 664 @ $1,94$981K · 2026-05-04
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 648 767 @ $0,55$354K · 2026-03-19
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 31 888 @ $0,65$21K · 2026-03-18
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 12 500 @ $0,78$10K · 2026-03-17
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 9 700 @ $0,83$8K · 2026-03-16
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 39 579 @ $0,85$34K · 2026-03-13
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 24 200 @ $1,11$27K · 2026-03-10
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 66 168 @ $1,14$75K · 2026-03-09
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 44 064 @ $1,30$57K · 2026-03-06
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 35 357 @ $1,50$53K · 2026-03-05
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 74 615 @ $1,66$124K · 2026-03-04
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 70 616 @ $1,91$135K · 2026-03-03
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 100 000 @ $1,98$198K · 2026-03-02
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 16 000 @ $2,29$37K · 2026-03-02
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 100 298 @ $2,12$212K · 2026-02-27
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 1 312 @ $5,01$7K · 2026-02-26
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 9 191 @ $6,05$56K · 2026-02-25
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Sold 13 917 @ $7,43$103K · 2026-02-24
    • CETERA WEALTH SERVICES, LLC10% owner · Class A Ordinary Shares, par value US$0.000625Bought 1 298 172 @ $7,20$9,3M · 2026-02-24

    Short positioning

    46.3Kshares short+120.6% vs prior
    1days to cover
    39.8%short of daily vol
    130fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RPGL.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · 2026-07-30
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-05-04 00:00 UTCINSIDER2 insider transactions — 2026-05 · $2.0M gross
    2026-05-04INSIDERNg Hao Feng transacted 505.7k sh Class A Ordinary Shares — Director, 10% owner ~$981k
    2026-04-03FILINGPROSPECTUS →
    2026-03-19 00:00 UTCINSIDER13 insider transactions — 2026-03 · net sell $1.1M
    2026-03-19INSIDERCETERA WEALTH SERVICES, LLC sold 648.8k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$354k
    2026-03-18INSIDERCETERA WEALTH SERVICES, LLC sold 31.9k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$21k
    2026-03-17INSIDERCETERA WEALTH SERVICES, LLC sold 12.5k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$10k
    2026-03-16INSIDERCETERA WEALTH SERVICES, LLC sold 9.7k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$8k
    2026-03-13INSIDERCETERA WEALTH SERVICES, LLC sold 39.6k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$34k
    2026-03-10INSIDERCETERA WEALTH SERVICES, LLC sold 24.2k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$27k
    2026-03-09INSIDERCETERA WEALTH SERVICES, LLC sold 66.2k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$75k
    2026-03-06INSIDERCETERA WEALTH SERVICES, LLC sold 44.1k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$57k
    2026-03-05INSIDERCETERA WEALTH SERVICES, LLC sold 35.4k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$53k
    2026-03-04INSIDERCETERA WEALTH SERVICES, LLC sold 74.6k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$124k
    2026-03-03INSIDERCETERA WEALTH SERVICES, LLC sold 70.6k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$135k
    2026-03-02INSIDERCETERA WEALTH SERVICES, LLC sold 100.0k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$198k
    2026-03-02INSIDERCETERA WEALTH SERVICES, LLC sold 16.0k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$37k
    2026-02-27 00:00 UTCINSIDER5 insider transactions — 2026-02 · net buy $9.0M
    2026-02-27INSIDERCETERA WEALTH SERVICES, LLC sold 100.3k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$212k
    2026-02-26INSIDERCETERA WEALTH SERVICES, LLC sold 1.3k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$7k
    2026-02-25INSIDERCETERA WEALTH SERVICES, LLC sold 9.2k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$56k
    2026-02-24INSIDERCETERA WEALTH SERVICES, LLC sold 13.9k sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$103k
    2026-02-24INSIDERCETERA WEALTH SERVICES, LLC bought 1.30M sh Class A Ordinary Shares, par value US$0.000625 — 10% owner ~$9.35M
    2026-01-29FILINGPROSPECTUS →
    2025-12-15FILINGANNUAL REPORT →
    2024-04-30 20:12 UTCEARNINGSAnnual results — FY 2024 Revenue INR 5.82B · Net INR 876.6M
    2023-04-28 21:20 UTCEARNINGSAnnual results — FY 2023 Revenue INR 5.13B · Net INR 676.4M
    2022-04-29 18:23 UTCEARNINGSAnnual results — FY 2022 Revenue INR 4.40B · Net INR 514.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage